Junyan Tao1, Diego F Calvisi2, Sarangarajan Ranganathan3, Antonio Cigliano2, Lili Zhou3,4, Sucha Singh3, Lijie Jiang1, Biao Fan1, Luigi Terracciano5, Sorin Armeanu-Ebinger6, Silvia Ribback2, Frank Dombrowski2, Matthias Evert2, Xin Chen1,7, Satdarshan P S Monga3. 1. Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA. 2. Institute of Pathology, University of Greifswald, Greifswald, Germany. 3. Department of Pathology, University of Pittsburgh, School of Medicine, Pittsburgh, PA. 4. The Second Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, P. R. China. 5. Institute of Pathology, University Hospital Basel, Basel, Switzerland. 6. Department of Pediatric Surgery and Pediatric Urology, Children's University Hospital Tuebingen, Tuebingen, Germany. 7. Liver Center, University of California, San Francisco, CA.
Abstract
BACKGROUND & AIMS: Aberrant activation of β-catenin and Yes-associated protein 1 (Yap1) signaling pathways have been associated with the development of multiple tumor types. Yap functions as a transcriptional coactivator by interacting with TEA domain DNA binding proteins. We investigated the interactions among these pathways during hepatic tumorigenesis. METHODS: We used immunohistochemical analysis to determine expression of β-catenin and Yap1 in liver cancer specimens collected from patients in Europe and the United States, consisting of 104 hepatocellular carcinoma, 62 intrahepatic cholangiocarcinoma, and 94 hepatoblastoma samples. We assessed β-catenin and Yap1 signaling and interactions in hepatoblastoma cell lines ((HuH6, HepG2, HepT1, HC-AFW1, HepG2, and HC-AFW1); proteins were knocked down with small interfering RNAs, and effects on proliferation and cell death were measured. Sleeping beauty-mediated hydrodynamic transfection was used to overexpress constitutively active forms of β-catenin (ΔN90/β-catenin) and Yap1 (YapS127A) in livers of mice; tissues were collected, and histological and immunohistochemical analyses were performed. RESULTS: We observed nuclear localization of β-catenin and Yap1 in 79% of hepatoblastoma samples but not in most hepatocellular carcinoma or intrahepatic cholangiocarcinoma samples. Yap1 and β-catenin coprecipitated in hepatoblastoma but not hepatocellular carcinoma cells. Small interfering RNA-mediated knockdown of Yap1 or β-catenin in hepatoblastoma cells reduced proliferation in an additive manner. Knockdown of Yap1 reduced its ability to coactivate transcription with β-catenin; β-catenin inhibitors inactivated Yap1. Overexpression of constitutively active forms of Yap1 and β-catenin in mouse liver led to rapid tumorigenesis, with 100% mortality by 11 weeks. Tumor cells expressed both proteins, and human hepatoblastoma cells expressed common targets of their 2 signaling pathways. Yap1 binding of TEA domain factors was required for tumorigenesis in mice. CONCLUSIONS: β-catenin and the transcriptional regulator Yap1 interact physically and are activated in most human hepatoblastoma tissues; overexpression of activated forms of these proteins in livers of mice leads to rapid tumor development. Further analysis of these mice will allow further studies of these pathways in hepatoblastoma pathogenesis and could lead to the identification of new therapeutic targets.
BACKGROUND & AIMS: Aberrant activation of β-catenin and Yes-associated protein 1 (Yap1) signaling pathways have been associated with the development of multiple tumor types. Yap functions as a transcriptional coactivator by interacting with TEA domain DNA binding proteins. We investigated the interactions among these pathways during hepatic tumorigenesis. METHODS: We used immunohistochemical analysis to determine expression of β-catenin and Yap1 in liver cancer specimens collected from patients in Europe and the United States, consisting of 104 hepatocellular carcinoma, 62 intrahepatic cholangiocarcinoma, and 94 hepatoblastoma samples. We assessed β-catenin and Yap1 signaling and interactions in hepatoblastoma cell lines ((HuH6, HepG2, HepT1, HC-AFW1, HepG2, and HC-AFW1); proteins were knocked down with small interfering RNAs, and effects on proliferation and cell death were measured. Sleeping beauty-mediated hydrodynamic transfection was used to overexpress constitutively active forms of β-catenin (ΔN90/β-catenin) and Yap1 (YapS127A) in livers of mice; tissues were collected, and histological and immunohistochemical analyses were performed. RESULTS: We observed nuclear localization of β-catenin and Yap1 in 79% of hepatoblastoma samples but not in most hepatocellular carcinoma or intrahepatic cholangiocarcinoma samples. Yap1 and β-catenin coprecipitated in hepatoblastoma but not hepatocellular carcinoma cells. Small interfering RNA-mediated knockdown of Yap1 or β-catenin in hepatoblastoma cells reduced proliferation in an additive manner. Knockdown of Yap1 reduced its ability to coactivate transcription with β-catenin; β-catenin inhibitors inactivated Yap1. Overexpression of constitutively active forms of Yap1 and β-catenin in mouse liver led to rapid tumorigenesis, with 100% mortality by 11 weeks. Tumor cells expressed both proteins, and humanhepatoblastoma cells expressed common targets of their 2 signaling pathways. Yap1 binding of TEA domain factors was required for tumorigenesis in mice. CONCLUSIONS: β-catenin and the transcriptional regulator Yap1 interact physically and are activated in most humanhepatoblastoma tissues; overexpression of activated forms of these proteins in livers of mice leads to rapid tumor development. Further analysis of these mice will allow further studies of these pathways in hepatoblastoma pathogenesis and could lead to the identification of new therapeutic targets.
Authors: T Mizuno; H Murakami; M Fujii; F Ishiguro; I Tanaka; Y Kondo; S Akatsuka; S Toyokuni; K Yokoi; H Osada; Y Sekido Journal: Oncogene Date: 2012-01-30 Impact factor: 9.867
Authors: Yi Liu-Chittenden; Bo Huang; Joong Sup Shim; Qian Chen; Se-Jin Lee; Robert A Anders; Jun O Liu; Duojia Pan Journal: Genes Dev Date: 2012-06-07 Impact factor: 11.361
Authors: Sorin Armeanu-Ebinger; Julia Wenz; Guido Seitz; Ivo Leuschner; Rupert Handgretinger; Ulrike A Mau-Holzmann; Michael Bonin; Bence Sipos; Jörg Fuchs; Steven W Warmann Journal: PLoS One Date: 2012-05-30 Impact factor: 3.240
Authors: Haibo Bai; Nailing Zhang; Yang Xu; Qian Chen; Mehtab Khan; James J Potter; Suresh K Nayar; Toby Cornish; Gianfranco Alpini; Steven Bronk; Duojia Pan; Robert A Anders Journal: Hepatology Date: 2012-08-08 Impact factor: 17.425
Authors: Shanthi Ganesh; Martin L Koser; Wendy A Cyr; Girish R Chopda; Junyan Tao; Xue Shui; Bo Ying; Dongyu Chen; Purva Pandya; Edmond Chipumuro; Zakir Siddiquee; Kevin Craig; Chengjung Lai; Henryk Dudek; Satdarshan P Monga; Weimin Wang; Bob D Brown; Marc T Abrams Journal: Mol Cancer Ther Date: 2016-07-07 Impact factor: 6.261
Authors: Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores Journal: Nat Rev Gastroenterol Hepatol Date: 2020-06-30 Impact factor: 46.802
Authors: Shanshan Zhang; Xinhua Song; Dan Cao; Zhong Xu; Biao Fan; Li Che; Junjie Hu; Bin Chen; Mingjie Dong; Maria G Pilo; Antonio Cigliano; Katja Evert; Silvia Ribback; Frank Dombrowski; Rosa M Pascale; Antonio Cossu; Gianpaolo Vidili; Alberto Porcu; Maria M Simile; Giovanni M Pes; Gianluigi Giannelli; John Gordan; Lixin Wei; Matthias Evert; Wenming Cong; Diego F Calvisi; Xin Chen Journal: J Hepatol Date: 2017-07-19 Impact factor: 25.083
Authors: James M Dolezal; Huabo Wang; Sucheta Kulkarni; Laura Jackson; Jie Lu; Sarangarajan Ranganathan; Eric S Goetzman; Sivakama S Bharathi; Kevin Beezhold; Craig A Byersdorfer; Edward V Prochownik Journal: J Biol Chem Date: 2017-04-21 Impact factor: 5.157